Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Tegoprubart Phase 2 BESTOW kidney transplant data will be presented at TTS 2026 in Sydney.

Rhea-AI Summary

Eledon Pharmaceuticals (ELDN)/b) will deliver an oral presentation on the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection at the International Congress of The Transplantation Society in Sydney, Australia, held from September 20–23, 2026.The Phase 2 BESTOW trial and its extension will be presented by Andrew Adams, M.D., Ph.D., in the “Novel immunosuppression” session on Tuesday, September 22, 2026, from 8:00AM to 9:00AM AEST.

Key Terms

phase 2, immunosuppression

2 terms

phase 2 medical

"Phase 2 BESTOW trial and the BESTOW EXTENSION"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

immunosuppression medical

"Session Title: Novel immunosuppression"

Immunosuppression is the lowering of the immune system’s ability to fight infections and other threats, either from drugs, medical treatments, or underlying disease. For investors it matters because products or conditions that cause immunosuppression change a drug’s safety profile, patient eligibility, regulatory hurdles and market size—think of it like turning down a building’s alarm system, which can reduce false alarms but raises the risk of real break‑ins and affects downstream costs and demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026.

Details of the presentation are below:

Oral Presentation

Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection

Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview

Session Title: Novel immunosuppression

Session Date and Time: Tuesday, September 22, 2026, from 8:00AM to 9:00AM AEST

Session Room: Room C4.9

Presentation Time: 8:00AM AEST

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

FAQ

When and where within the congress will Eledon's tegoprubart data be presented?

The tegoprubart Phase 2 BESTOW and BESTOW EXTENSION data will be presented in the “Novel immunosuppression” session on Tuesday, September 22, 2026, from 8:00AM to 9:00AM AEST in Room C4.9, with the presentation scheduled at 8:00AM AEST.